{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:40:43Z","timestamp":1791434443510,"version":"4.3.3"},"reference-count":130,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007342","name":"Hamdard National Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["IIRP\/SG-0687\/2021"],"award-info":[{"award-number":["IIRP\/SG-0687\/2021"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejmech.2025.118411","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T16:29:08Z","timestamp":1764779348000},"page":"118411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Pharmacophore-guided review of EGFR-targeted anticancer drugs with gefitinib as a reference"],"prefix":"10.1016","volume":"303","author":[{"family":"Meenu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khursheed Ahmad","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Shaquiquzzaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivam","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Barkha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharba","family":"Tasneem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mymoona","family":"Akhter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Kaleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suruchi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6420-8757","authenticated-orcid":false,"given":"M.","family":"Mumtaz Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118411_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2025.118411_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2025.118411_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118411_bib4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.gene.2005.10.018","article-title":"Epidermal growth factor receptor (EGFR) signaling in cancer","volume":"366","author":"Normanno","year":"2006","journal-title":"Gene"},{"key":"10.1016\/j.ejmech.2025.118411_bib5","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/14728222.2023.2218613","article-title":"Targeting the EGFR signaling pathway in cancer therapy: what's new in 2023?","volume":"27","author":"Halder","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2025.118411_bib6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.gene.2005.10.018","article-title":"Epidermal growth factor receptor (EGFR) signaling in cancer","volume":"366","author":"Normanno","year":"2006","journal-title":"Gene"},{"key":"10.1016\/j.ejmech.2025.118411_bib7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7150\/ijms.1.101","article-title":"Tyrosine Kinase \u2013 Role and significance in cancer","volume":"1","author":"Paul","year":"2004","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.ejmech.2025.118411_bib8","series-title":"Therapeutic Advances of Targeting Receptor Tyrosine Kinases in Cancer","author":"Tomuleasa","year":"2024"},{"key":"10.1016\/j.ejmech.2025.118411_bib9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-018-0782-4","article-title":"Mechanisms of receptor tyrosine kinase activation in cancer","volume":"17","author":"Du","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2025.118411_bib10","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1159\/000279388","article-title":"EGFR signaling and drug discovery","volume":"77","author":"Lurje","year":"2010","journal-title":"Oncology"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118411_bib11","first-page":"707","article-title":"EGFR, growth factors","volume":"2","author":"Bhutani","year":"2017","journal-title":"Cancer Ther."},{"key":"10.1016\/j.ejmech.2025.118411_bib12","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.2174\/092986706779026174","article-title":"Targeting the EGFR pathway for cancer therapy","volume":"13","author":"Johnston","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118411_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032651","article-title":"Small molecule EGFR inhibitors as anti-cancer agents: discovery, mechanisms of action, and opportunities","volume":"24","author":"Zubair","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118411_bib14","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"Harrison","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2025.118411_bib15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.canep.2015.02.003","article-title":"Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: the Spanish REASON study","volume":"39","author":"Esteban","year":"2015","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.ejmech.2025.118411_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0143515","article-title":"Molecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology - mainland China subset analysis of the PIONEER study","volume":"10","author":"Shi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118411_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103811","article-title":"A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy","volume":"99","author":"Ayati","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118411_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1742-4658.2009.07448.x","article-title":"Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer","volume":"277","author":"Mitsudomi","year":"2010","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2025.118411_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2009.03992.x","article-title":"Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy","volume":"158","author":"Martinelli","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ejmech.2025.118411_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13216391","article-title":"EGFR-targeted therapies\u202f: a literature review","volume":"13","author":"Sha","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejmech.2025.118411_bib21","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10555-017-9687-8","article-title":"EGFR-targeted therapies in the post-genomic era","volume":"36","author":"Xu","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ejmech.2025.118411_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113523","article-title":"Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy","volume":"221","author":"Ayati","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118411_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-34627-5","article-title":"A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations","volume":"13","author":"Deng","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118411_bib24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1042\/BJ20121513","article-title":"Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain","volume":"448","author":"Park","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2025.118411_bib25","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/j.cllc.2019.12.003","article-title":"Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non e Small-Cell Lung Cancer : a Clash of the Generations","volume":"21","author":"Shah","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.ejmech.2025.118411_bib26","first-page":"S23","article-title":"EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients, Transl","volume":"8","author":"Karachaliou","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118411_bib27","doi-asserted-by":"crossref","first-page":"S235","DOI":"10.21037\/tlcr.2019.04.20","article-title":"Epidermal growth factor receptor first generation tyrosine-kinase inhibitors","volume":"8","author":"Martinez-marti","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118411_bib28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejmech.2017.07.023","article-title":"How to train your inhibitor: design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors","volume":"142","author":"Milik","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118411_bib29","first-page":"9","article-title":"Future Journal of Pharmaceutical Sciences Recent advances in 4-aminoquinazoline based scaffold derivatives targeting EGFR kinases as anticancer agents","volume":"2","author":"Ismail","year":"2016","journal-title":"Futur. J. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2025.118411_bib30","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.2147\/DDDT.S119162","article-title":"Three generations of epidermal growth factor receptor tyrosine kinase inhibitors developed to revolutionize the therapy of lung cancer","volume":"10","author":"Zhang","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ejmech.2025.118411_bib31","article-title":"EGFR as therapeutic target to develop new generation tyrosine kinase inhibitors against breast cancer: a critical review, results","volume":"7","author":"Mariam Raju","year":"2024","journal-title":"Chem"},{"key":"10.1016\/j.ejmech.2025.118411_bib32","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK -Positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118411_bib33","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1248\/bpb.b23-00924","article-title":"New directions for advanced targeting strategies of EGFR signaling in cancer","volume":"47","author":"Zhou","year":"2024","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2025.118411_bib34","doi-asserted-by":"crossref","DOI":"10.1186\/s43042-020-00107-y","article-title":"Structure-based design of some quinazoline derivatives as epidermal growth factor receptor inhibitors","volume":"21","author":"Ibrahim","year":"2020","journal-title":"Egypt. J. Med. Hum. Genet."},{"key":"10.1016\/j.ejmech.2025.118411_bib35","doi-asserted-by":"crossref","DOI":"10.1051\/e3sconf\/202455304013","article-title":"Research on targeted drug design based on computer technology","volume":"553","author":"Xu","year":"2024","journal-title":"E3S Web Conf."},{"key":"10.1016\/j.ejmech.2025.118411_bib36","doi-asserted-by":"crossref","first-page":"13384","DOI":"10.3390\/molecules200713384","article-title":"Molecular docking and structure-based drug design strategies","volume":"20","author":"Ferreira","year":"2015","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118411_bib37","doi-asserted-by":"crossref","unstructured":"J. Singh, K.L. Khanduja, P.K. Avti, Unravelling benzazepines and aminopyrimidine as multi-target therapeutic repurposing drugs for EGFR V774M mutation in neuroglioma patients, Bioimpacts 14 (n.d.) 28876. https:\/\/doi.org\/10.34172\/bi.2023.28876.","DOI":"10.34172\/bi.2023.28876"},{"key":"10.1016\/j.ejmech.2025.118411_bib38","doi-asserted-by":"crossref","DOI":"10.5936\/csbj.201302011","article-title":"Current progress in structure-based rational drug design marks a new mindset in drug discovery","volume":"5","author":"Lounnas","year":"2013","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.ejmech.2025.118411_bib39","doi-asserted-by":"crossref","first-page":"45842","DOI":"10.1021\/acsomega.4c04639","article-title":"Design and optimization of quinazoline derivatives as potent EGFR inhibitors for lung cancer treatment\u202f: a comprehensive QSAR , ADMET , and molecular modeling investigation","volume":"9","author":"Moussaoui","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2025.118411_bib40","unstructured":"A. Peter, Principle and applications of Structure B ased D rug D esign drug designing : open access, (n.d.) 2169. https:\/\/doi.org\/10.35248\/2169-0138.23.12.235."},{"key":"10.1016\/j.ejmech.2025.118411_bib41","doi-asserted-by":"crossref","first-page":"94","DOI":"10.34133\/hds.0094","article-title":"A structure-based allosteric modulator design paradigm","volume":"3","author":"Li","year":"2023","journal-title":"Heal. Data Sci."},{"key":"10.1016\/j.ejmech.2025.118411_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0158898","article-title":"GeauxDock: accelerating structure-based virtual screening with heterogeneous computing","volume":"11","author":"Fang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118411_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep16924","article-title":"Large-scale computational screening identifies first in class multitarget inhibitor of EGFR kinase and BRD4","volume":"5","author":"Allen","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118411_bib44","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.2174\/138945008786949432","article-title":"Molecular docking algorithms","volume":"9","author":"Dias","year":"2008","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejmech.2025.118411_bib45","doi-asserted-by":"crossref","first-page":"10150","DOI":"10.3390\/molecules190710150","article-title":"Challenges, applications, and recent advances of protein-ligand docking in structure-based drug design","volume":"19","author":"Grinter","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118411_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmolb.2021.657222","article-title":"Perspectives on high-throughput ligand\/protein docking with martini MD simulations","volume":"8","author":"Souza","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ejmech.2025.118411_bib47","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/jcc.21601","article-title":"Predicting the accuracy of protein\u2013ligand docking on homology models","volume":"32","author":"Bordogna","year":"2011","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2025.118411_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105920","article-title":"How good are AlphaFold models for docking-based virtual screening?","volume":"26","author":"Scardino","year":"2023","journal-title":"IScience"},{"key":"10.1016\/j.ejmech.2025.118411_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2023.1265573","article-title":"Navigating bioactivity space in anti-tubercular drug discovery through the deployment of advanced machine learning models and cheminformatics tools: a molecular modeling based retrospective study","volume":"14","author":"Bhowmik","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118411_bib50","author":"Alakhdar"},{"key":"10.1016\/j.ejmech.2025.118411_bib51","doi-asserted-by":"crossref","first-page":"151","DOI":"10.5267\/j.ccl.2023.8.001","article-title":"Current trends of chemoinformatics and computer chemistry in drug design: a review","volume":"13","author":"Myrko","year":"2024","journal-title":"Curr. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118411_bib52","doi-asserted-by":"crossref","first-page":"100713","DOI":"10.1016\/j.drup.2020.100713","article-title":"This is the peer reviewed version of the following article, Repurposing Old Drugs to Fight Multidrug Resistant Cancers","volume":"52","author":"Dini\u0107","year":"2020","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.ejmech.2025.118411_bib53","doi-asserted-by":"crossref","first-page":"5054","DOI":"10.1021\/acs.jcim.1c00589","article-title":"Pharmacoprint: a combination of a pharmacophore fingerprint and artificial intelligence as a tool for computer-aided drug design","volume":"61","author":"Warszycki","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2025.118411_bib54","first-page":"1","article-title":"Next-generation EGFR tyrosine kinase inhibitors for treating EGFR-mutant lung cancer beyond first line","volume":"3","author":"Sullivan","year":"2016","journal-title":"Front. Med."},{"key":"10.1016\/j.ejmech.2025.118411_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ijo.2021.5270","article-title":"Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer","volume":"59","author":"He","year":"2021","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2025.118411_bib56","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors","volume":"29","author":"Westover","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2025.118411_bib57","first-page":"4120","article-title":"Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations, Transl","volume":"10","author":"He","year":"2021","journal-title":"Lung Cancer Res"},{"key":"10.1016\/j.ejmech.2025.118411_bib58","first-page":"123","article-title":"Erlotinib in previously treated Non\u2013small-cell lung cancer","volume":"353","author":"A","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118411_bib59","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive breast cancer : geyer","volume":"355","author":"Geyer","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118411_bib60","doi-asserted-by":"crossref","first-page":"161","DOI":"10.6004\/jnccn.2013.0024","article-title":"Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers","volume":"11","author":"Yu","year":"2013","journal-title":"JNCCN J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ejmech.2025.118411_bib61","first-page":"1","article-title":"Brigatinib can inhibit proliferation and induce apoptosis of human immortalized keratinocyte cells","volume":"16","author":"Yang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118411_bib62","first-page":"1","article-title":"Real-world data of dacomitinib as first-line treatment for patients with EGFR-Mutant non-small-cell lung cancer","volume":"15","author":"Shin","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118411_bib63","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1080\/14656566.2020.1746269","article-title":"Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?","volume":"21","author":"Bergonzini","year":"2020","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.118411_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2022.105787","article-title":"Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R\/T790M, and L858R\/T790M\/C797S forms of EGFR","volume":"147","author":"Todsaporn","year":"2022","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.ejmech.2025.118411_bib65","doi-asserted-by":"crossref","first-page":"S247","DOI":"10.21037\/tlcr.2019.06.01","article-title":"Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer","volume":"8","author":"Wright","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118411_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-021-01391-x","article-title":"Correction to: discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance (molecular cancer","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2025.118411_bib67","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s40265-016-0606-z","article-title":"Olmutinib: first global approval","volume":"76","author":"Kim","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118411_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26216677","article-title":"Globally approved egfr inhibitors: insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism","volume":"26","author":"Abourehab","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118411_bib69","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1039\/D3RA02347H","article-title":"Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review","volume":"13","author":"Mansour","year":"2023","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2025.118411_bib70","article-title":"Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors","volume":"2","author":"Du","year":"2021","journal-title":"Innovation"},{"key":"10.1016\/j.ejmech.2025.118411_bib71","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.canlet.2016.11.008","article-title":"EAI045: the fourth-generation EGFR inhibitor overcoming T790M and C797S resistance","volume":"385","author":"Wang","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2025.118411_bib72","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR (T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118411_bib73","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-4668","article-title":"Abstract 4668: characterization of fourth-generation EGFR inhibitors in binding experiments with C797S mutant EGFR and cell-based assays with osimertinib-resistant non-small cell lung cancer cell lines","volume":"84","author":"Melis","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118411_bib74","first-page":"3929","article-title":"Fourth-generation epidermal growth factor receptor-tyrosine kinases inhibitors: hope and challenges, Transl","volume":"13","author":"Su","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118411_bib75","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/JTO.0b013e31824177ea","article-title":"Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer","volume":"7","author":"Siegfried","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2025.118411_bib76","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.drup.2019.04.002","article-title":"The TICking clock of EGFR therapy resistance in glioblastoma: target Independence or target compensation","volume":"43","author":"Saleem","year":"2019","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.ejmech.2025.118411_bib77","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1517\/14712590902735795","article-title":"Mechanisms of tumor resistance to EGFR-targeted therapies","volume":"13","author":"Hopper-Borge","year":"2009","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2025.118411_bib78","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.2147\/OTT.S66502","article-title":"Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives","volume":"7","author":"Cheng","year":"2014","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejmech.2025.118411_bib79","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0294-2020","article-title":"Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer","volume":"30","author":"Abdayem","year":"2021","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.ejmech.2025.118411_bib80","doi-asserted-by":"crossref","first-page":"15477","DOI":"10.1021\/acs.jmedchem.3c01669","article-title":"Discovery of a hydroxylamine-based brain-penetrant EGFR inhibitor for metastatic non-small-cell lung cancer","volume":"66","author":"Hill","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118411_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-022-01534-8","article-title":"Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers","volume":"21","author":"Kolesar","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2025.118411_bib82","doi-asserted-by":"crossref","DOI":"10.1038\/s12276-018-0202-2","article-title":"Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer","volume":"51","author":"Byeon","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejmech.2025.118411_bib83","article-title":"Targeted inhibitors of EGFR: structure, biology, biomarkers, and clinical applications","author":"Shaban","year":"2024","journal-title":"Cells 13"},{"key":"10.1016\/j.ejmech.2025.118411_bib84","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2174\/187152012800228652","article-title":"Recent developments of small molecule EGFR inhibitors based on the quinazoline core scaffolds","volume":"12","author":"Liu","year":"2012","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118411_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112640","article-title":"Novel quinazoline-based EGFR kinase inhibitors: a review focussing on SAR and molecular docking studies (2015-2019)","volume":"204","author":"Bhatia","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118411_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fddsv.2024.1365318","article-title":"Editorial: discovery of EGFR tyrosine kinase inhibitors for cancer treatment","volume":"4","author":"Mahalapbutr","year":"2024","journal-title":"Front. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118411_bib87","doi-asserted-by":"crossref","first-page":"10272","DOI":"10.1021\/acs.jmedchem.9b01169","article-title":"Start selective and rigidify: the discovery path toward a next generation of EGFR tyrosine kinase inhibitors","volume":"62","author":"Engelhardt","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118411_bib88","first-page":"8191","article-title":"Identification and pharmacological analysis of high efficacy small molecule inhibitors of EGF-EGFR interactions in clinical treatment of non-small cell lung carcinoma: a computational approach, Asian Pacific","volume":"16","author":"Gudala","year":"2016","journal-title":"J. Cancer Prev."},{"key":"10.1016\/j.ejmech.2025.118411_bib89","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.ctrv.2014.06.010","article-title":"Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions","volume":"40","author":"Peters","year":"2014","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.ejmech.2025.118411_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-15050-8","article-title":"Design, synthesis, in vitro biological assessment and molecular modeling insights for novel 3-(naphthalen-1-yl)-4,5-dihydropyrazoles as anticancer agents with potential EGFR inhibitory activity","volume":"12","author":"Eldehna","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118411_bib91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0282586","article-title":"Anticancer derivative of the natural alkaloid, theobromine, inhibiting EGFR protein: Computer-aided drug discovery approach","volume":"18","author":"Eissa","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118411_bib92","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1080\/14756366.2022.2062752","article-title":"Design, synthesis, and anti-cancer evaluation of new pyrido[2,3-d]pyrimidin-4(3H)-one derivatives as potential EGFRWT and EGFRT790M inhibitors and apoptosis inducers","volume":"37","author":"Elzahabi","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118411_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.prerep.2025.100030","article-title":"Design, and evaluation of in-silico anti-cancer activity of novel gefitinib analogues against 21 target proteins","volume":"3","author":"Ushna","year":"2025","journal-title":"Pharmacol. Res. - Reports"},{"key":"10.1016\/j.ejmech.2025.118411_bib94","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3390\/biophysica3010013","article-title":"Structural analysis of interactions between epidermal growth factor receptor (EGFR) mutants and their inhibitors","volume":"3","author":"Guo","year":"2023","journal-title":"Biophysica"},{"key":"10.1016\/j.ejmech.2025.118411_bib95","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/10799893.2018.1426603","article-title":"Computational screening, ensemble docking and pharmacophore analysis of potential gefitinib analogues against epidermal growth factor receptor","volume":"38","author":"Bommu","year":"2018","journal-title":"J. Recept. Signal Transduction"},{"key":"10.1016\/j.ejmech.2025.118411_bib96","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/cbdd.12977","article-title":"Epidermal growth factor receptor (EGFR) structure-based bioactive pharmacophore models for identifying next-generation inhibitors against clinically relevant EGFR mutations","volume":"90","author":"Panicker","year":"2017","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2025.118411_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0311527","article-title":"Integration of pharmacophore-based virtual screening, molecular docking, ADMET analysis, and MD simulation for targeting EGFR: a comprehensive drug discovery study using commercial databases","volume":"19","author":"Alanzi","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118411_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.132531","article-title":"Pharmacophore modeling, virtual screening, molecular docking and dynamics studies for the discovery of HER2-tyrosine kinase inhibitors: an in-silico approach","volume":"1257","author":"Matada","year":"2022","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2025.118411_bib99","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s10822-025-00680-7","article-title":"Vitro and in silico evaluation of synthesized 4-anilinoquinazoline derivatives as potential anticancer agents","volume":"39","author":"Maulana","year":"2025","journal-title":"J. Comput. Aided. Mol. Des."},{"key":"10.1016\/j.ejmech.2025.118411_bib100","doi-asserted-by":"crossref","first-page":"2400811","DOI":"10.1002\/adts.202400811","article-title":"Pharmacophore-based modeling, synthesis, and biological evaluation of novel quinazoline\/quinoline derivatives: Discovery of EGFR inhibitors with low nanomolar activity","volume":"8","author":"Evren","year":"2025","journal-title":"Adv. Theory Simulations"},{"key":"10.1016\/j.ejmech.2025.118411_bib101","doi-asserted-by":"crossref","first-page":"1456743","DOI":"10.3389\/fchem.2025.1456743","article-title":"Anti-cancer activity of synthetic gefitinib-1,2,3-triazole derivatives against hela cells via induction of apoptosis","volume":"13","author":"Hu","year":"2025","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2025.118411_bib102","first-page":"1","article-title":"Discovery of gefitinib-1,2,3-triazole derivatives against lung cancer via inducing apoptosis and inhibiting the colony formation","volume":"14","author":"Gao","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118411_bib103","article-title":"Synthesis and in vitro antitumor activity evaluation of Gefitinib-1,2,3-Triazole derivatives","volume":"29","author":"Liu","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118411_bib104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/molecules29225438","article-title":"Synthesis of novel gefitinib-conjugated 1 , 2 , 3-Triazole derivatives and their effect of inducing DNA damage and apoptosis in tumor Cells","volume":"29","author":"Wu","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118411_bib105","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.4314\/bcse.v37i5.10","article-title":"Design, synthesis, crystal structure and biological evaluation of novel 4-arylaminoquin- azoline derivatives as potent cytotoxic agents","volume":"37","author":"Han","year":"2023","journal-title":"Bull. Chem. Soc. Ethiop."},{"key":"10.1016\/j.ejmech.2025.118411_bib106","first-page":"1","article-title":"Discovery of potent EGFR inhibitors with 6-Arylureido-4-anilinoquinazoline derivatives","volume":"12","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118411_bib107","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00044-020-02634-0","article-title":"CHEMISTRY novel amide analogues of quinazoline carboxylate display selective antiproliferative activity and potent EGFR inhibition","author":"Malhotra","year":"2020","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2025.118411_bib108","doi-asserted-by":"crossref","first-page":"1800381","DOI":"10.1002\/ardp.201800381","article-title":"Synthesis of novel gefitinib-based derivatives and their anticancer activity","volume":"352","author":"Sharma","year":"2019","journal-title":"Arch. Pharm. (Weinheim)."},{"key":"10.1016\/j.ejmech.2025.118411_bib109","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1016\/j.bmc.2016.01.003","article-title":"Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M\/L858R mutant","volume":"24","author":"Qin","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118411_bib110","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.bmcl.2016.02.009","article-title":"Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors","volume":"26","author":"Qin","year":"2016","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118411_bib111","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.1016\/j.arabjc.2016.09.019","article-title":"Pharmacophore modeling, 3D-QSAR, docking and ADME prediction of quinazoline based EGFR inhibitors","volume":"12","author":"Verma","year":"2019","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.ejmech.2025.118411_bib112","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1016\/j.bmcl.2014.09.056","article-title":"Optimization of gefitinib analogues with potent anticancer activity","volume":"24","author":"Yin","year":"2014","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118411_bib113","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/1062936X.2010.548830","article-title":"Pharmacophore modelling, molecular docking and virtual screening for EGFR (HER 1) tyrosine kinase inhibitors","volume":"22","author":"Gupta","year":"2011","journal-title":"SAR QSAR Environ. Res."},{"key":"10.1016\/j.ejmech.2025.118411_bib114","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1016\/j.bmc.2010.04.046","article-title":"Bioorganic & medicinal chemistry design and synthesis of novel gefitinib analogues with improved anti-tumor activity","volume":"18","author":"Wu","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118411_bib115","doi-asserted-by":"crossref","first-page":"935","DOI":"10.3390\/cryst15110935","article-title":"Synthesis, EGFR inhibitors, crystal structure, and molecular docking of 2-Amino-6-methoxy-4-(2-bromophenyl)-4H-benzo [h]chromene-3-carbonitrile","volume":"15","author":"Al-Dies","year":"2025","journal-title":"Crystals"},{"key":"10.1016\/j.ejmech.2025.118411_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.108106","article-title":"Bioorganic chemistry exploring 1 , 2 , 3-triazole-Schiff \u2019 s base hybrids as innovative EGFR inhibitors for the treatment of breast cancer : in vitro and in silico study","volume":"155","author":"Nawareg","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118411_bib117","first-page":"1","article-title":"New oxadiazole and pyrazoline derivatives as anti - proliferative agents targeting EGFR - TK : design , synthesis , biological evaluation and molecular docking study","author":"Serag","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118411_bib118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0298326","article-title":"Bioinformatics-driven discovery of novel EGFR kinase inhibitors as anti-cancer therapeutics: in silico screening and in vitro evaluation","volume":"19","author":"Radwan","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118411_bib119","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1016\/j.matpr.2022.04.315","article-title":"Materials today : proceedings molecular docking , synthesis , characterization and preliminary cytotoxic evaluation of new 1 , 3 , 4-Thiadiazole derivatives as EGFR inhibitors","volume":"65","author":"Abdulkhaleq","year":"2022","journal-title":"Mater. Today Proc."},{"key":"10.1016\/j.ejmech.2025.118411_bib120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073487","article-title":"Hybrid pharmacophore-and structure-based virtual screening pipeline to identify novel EGFR inhibitors that suppress non-small cell lung cancer cell growth","volume":"23","author":"Weng","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118411_bib121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2022.1027890","article-title":"Pharmacophore-based virtual screening approaches to identify novel molecular candidates against EGFR through comprehensive computational approaches and in-vitro studies","volume":"13","author":"Opo","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118411_bib122","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1080\/14756366.2021.1946044","article-title":"Design , synthesis , and analysis of antiproliferative and apoptosis-inducing activities of nitrile derivatives containing a benzofuran scaffold : EGFR inhibition assay and molecular modelling study","volume":"36","author":"Fares","year":"2021","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118411_bib123","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26051490","article-title":"Design and synthesis of non-covalent imidazo[1,2- a ]quinoxaline-based inhibitors of EGFR and, their anti-cancer assessment","volume":"26","author":"Kumar","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118411_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105325","article-title":"Design, synthesis, biological evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers","volume":"116","author":"Sherbiny","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118411_bib125","first-page":"353","article-title":"Pharmacophore modeling, 3D-QSAR, synthesis, and anti-lung cancer evaluation of novel thieno[2,3-d][1,2,3]triazines targeting EGFR","author":"Elrayess","year":"2020","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.ejmech.2025.118411_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.102994","article-title":"Identification of 2(1H)-pyrimidinones as potential EGFR T790M inhibitors for the treatment of gefitinib-resistant non-small cell lung cancer","volume":"89","author":"Huang","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118411_bib127","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1016\/j.bmc.2015.05.059","article-title":"Discovery of a novel class anti-proliferative agents and potential inhibitors of EGFR tyrosine kinases based on 4-anilinotetrahydropyrido[4,3-d]pyrimidine scaffold: design, synthesis and biological evaluations","volume":"23","author":"Zhang","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118411_bib128","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1248\/cpb.c15-00592","article-title":"Discovery of potent antiproliferative agents targeting EGFR tyrosine kinase based on the pyrido[3\u2019,2\u2019:4,5]thieno[3,2-d]pyrimidin-4-amine scaffold","volume":"63","author":"Aziz","year":"2015","journal-title":"Chem. Pharm. Bull. (Tokyo)."},{"key":"10.1016\/j.ejmech.2025.118411_bib129","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/cbdd.12383","article-title":"Synthesis and evaluation of salicylanilide derivatives as potential epidermal growth factor receptor inhibitors","volume":"85","author":"Hu","year":"2015","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2025.118411_bib130","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/j.ejmech.2010.02.032","article-title":"Synthesis and study of antiproliferative activity of novel thienopyrimidines on glioblastoma cells","volume":"45","author":"P\u00e9deboscq","year":"2010","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425011766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425011766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:42:44Z","timestamp":1781325764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425011766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":130,"alternative-id":["S0223523425011766"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118411","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacophore-guided review of EGFR-targeted anticancer drugs with gefitinib as a reference","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118411","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118411"}}